Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving oxidoreductase
Reexamination Certificate
2007-08-31
2010-11-16
Gitomer, Ralph (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving oxidoreductase
C424S009100
Reexamination Certificate
active
07833744
ABSTRACT:
The present invention relates, generally to a method of determining and assessing cytochrome P450 2C19-related (CYP2Cl9) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of13CO2exhaled by the subject upon intravenous or oral administration of a13C-labeled CYP2C19 substrate compound. The present invention is useful as a non-invasive, in vivo assay for evaluating CYP2C19 enzyme activity in a subject using the metabolite13CO2in expired breath, to phenotype individual subjects and to determine the selection, optimal dosage and timing of drug administration.
REFERENCES:
patent: 2004/0229222 (2004-11-01), Chui et al.
patent: 2007/0026480 (2007-02-01), Modak et al.
Bastien M. et al. Characterization of Cytochrome P450 2E1 Activity . . . Canadian J of Physiology and Pharmacology 76(7-8)756-763, 1998.
Tateishi T. et al. Omeprazole Does Not Affect Measured CYP3A4 Acitvity Using the Erythromycin Breath Test. British J of Pharmacology 40:411-412, 1995.
Klotz U. et al. CYP2C19 Polymorphism and Proton Pump Inhibitors. Basic & clinical Pharmacology & Toxicology. 95(1)2-8, 2004.
Poolsup N. et al. Pharmacogenetics and Psychopharmacotherapy. J of Clinical Pharmacy and Therapeutics 25(3)197-220, 2000.
Arefayene M. et al. Sequence Diversity and Functional Characterization of the 5′Regulatory Region of Human CYP2C19. Pharmacogenetics 13(4)199-206, 2003.
Desta Z. et al. Rapid Identification of the Hepatic Cytochrome P450 2C19 Activity Using a Novel and Noninvasive Patoprazole Breath Test. J of Pharmacology and Experimental Therapeutics. 329(1)297-305, 2009.
Tateishi, et al., “Omeprazole Does Not Affect Measured CYP3A4 Activity Using the Erythomycin Breath Test”,British J. Clinical Pharmacology, Oct. 1995, vol. 40., pp. 411-412.
Furuta, et al; “CYP2C19 Genotype Status and Effect of Omeprazole on Intragastric pH in Humans”,Clin. Pharmacol. Ther., May 1999, vol. 65., pp. 552-561.
Desta, et al; “Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism”,Clinical Pharmacokinetics, 2002, vol. 41(12)., pp. 913-958.
International Search Report (PCT/US07/77362); Date of Mailing Mar. 20, 2008; 2 pages.
Goldstein, “Clinical Relevance of Genetic Polymorphisms in the Human CYP2C Subfamily”,Br. J. Clin. Pharmacol., Oct. 2001, vol. 52., pp. 349-355.
Demorais, et al., “Identification of a New Genetic Defect Responsible for the Polymorphism of (S)-Mephenytoin Metabolism in Japanese”,Mol. Pharmacol., Oct. 1994, vol. 46., pp. 594-598.
Ibeanu, et al., “Identification of New Human CYP2C19 Alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian Poor Metabolizer of Mephenytoin”,J. Pharmacol. Exp. Ther., Sep. 1998, vol. 286., pp. 1490-1495.
Ibeanu, et al., “An Additional Defective Allele, CYP2C19*5, Contributes to the S-Mephenytoin Poor Metabolizer Phenotype in Caucasians”,Pharmacogenetics, Apr. 1998, vol. 8., pp. 129-135.
Ibeanu, et al., “A Novel Transversion in the Intron 5 Donor Splice Junction of CYP2C19 and a Sequence Polymorphism in Exon 3 Contribute to the Poor Metabolizer Phenotype for the Anticonvulsant Drug S-Mephenytoin”,J. Pharmacol. Exp. Ther., Aug. 1999, vol. 290., pp. 635-640.
Ferguson, et al., “A New Genetic Defect in Human CYP2C19: Mutation of the Initiation Codon Is Responsible for Poor Metabolism of S-Mephenytoin”,J. Pharmacol. Exp. Ther., Jan. 1998, vol. 284, pp. 356-361.
Sim, et al., “A Common Novel CYP2C19 Gene Variant Causes Ultrarapid Drug Metabolism Relevant for the Drug Response to Proton Pump Inhibitors and Antidepressants”,Clin, Pharmacol. Ther., Jan. 2006, vol. 79., pp. 103-113.
Lazarou, et al., “Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-Analysis of Prospective Studies”,J. Amer. Med. Assoc., Apr. 1998, vol. 279., pp. 1200-1205.
Furuta, et al., “Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter Pylori Infection and Peptic Ulcer”,Ann. Intern. Med., Dec. 1998, vol. 129., pp. 1027-1030.
Furuta, et al., “Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-Based Therapies”,Drug Metab. Pharmacokinet, Jun. 2005, vol. 20., pp. 153-167.
Hulot, et al., “Cytochrome P450 2C19 Loss-of-Function Polymorphism is a Major Determinant of Clopidogrel Responsiveness in Healthy Subjects”,Blood, Oct. 2006, vol. 108., pp. 2244-2247.
Roy, et al., “Development of a Substrate-Activity Based Approach to Identify the Major Human Liver P-450 Catalysts of Cyclophosphamide and Ifosfamide Activation Based on cDNA-Expressed Activities and Liver Microsomal P-450 Profiles”,Drug Metab. Dispos., Jun. 1997, vol. 27., pp. 655-666.
Rae, et al., “Triethylenethiophosphoramide is a Specific Inhibitor of Cytochrome P450 2B6: Implications for Cyclophosphamide Metabolism”,Drug. Metab. Dispos., May 2002, vol. 30., pp. 525-530.
Takada, et al., “Cytochrome P450 Pharmacogenetics as a Predictor of Toxicity and Clinical Responses to Pulse Cyclophosphamide in Lupus Nephritis”,Arthritis Rheum., Jul. 2004, vol. 50., pp. 2202-2210.
Lacroix, et al., “Glucose Naturally Labeled with Carbon-13: Use for Metabolic Studies in Man”,Science, Aug. 1973, vol. 181., pp. 455-446.
Modak, “Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring”, A. Amann, D Smith (ed). World Scientific, Singapore, 2005, pp. 457-478.
Desta Zeruesenay
Flockhart David A.
Kurogi Yasuhisa
Modak Anil S.
Cambridge Isotope Laboratories, Inc.
Ewing James F.
Foley & Lardner LLP
Gitomer Ralph
Morency Michel
LandOfFree
Methods to evaluate cytochrome P450 2C19 isoenzyme activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods to evaluate cytochrome P450 2C19 isoenzyme activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to evaluate cytochrome P450 2C19 isoenzyme activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4169882